Skip to main content

Table 1 Patient demographics and baseline characteristicsa

From: Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial

Demographics and characteristics Placebo
(n= 50)
Milnacipran
(n= 100)
Total
(N= 150)
Mean age (SD), years 54.0 (8.3) 54.5 (9.3) 54.3 (9.0)
Women, n (%) 48 (96.0) 96 (96.0) 144 (96.0)
Race, n (%)    
   White 47 (94.0) 96 (96.0) 143 (95.3)
   Nonwhite 3 (6.0) 4 (4.0) 7 (4.7)
Mean weight (SD), kg 77.3 (16.7) 80.2 (14.5) 79.2 (15.3)
Mean body mass index (SD), kg/m2 29.0 (6.1) 29.7 (5.2) 29.5 (5.5)
Mean SF-36 PCS score (SD) 41.3 (10.2) 41.6 (8.4) 41.5 (9.0)
Mean SF-36 MCS score (SD) 53.6 (11.3) 53.6 (9.0) 53.6 (9.8)
Mean FIQR total score (SD), range 0 to 100 21.4 (15.8) 19.4 (11.9) 20.1 (13.3)
Mean MAF global fatigue score (SD), range 1 to 50 21.4 (10.4) 20.7 (9.7) 21.0 (9.9)
Mean BPI average pain score (SD), range 0 to 10 2.5 (1.3) 2.3 (1.4) 2.3 (1.4)
Mean VAS pain score (SD), range 0 to 100 19.3 (11.6) 16.6 (9.6) 17.5 (10.3)
Mean VAS pain score (SD), pre-milnacipran exposureb 66.2 (14.7) 65.4 (13.0) 65.7 (13.6)
  1. aBaseline is defined as the randomization visit in this study. BPI = Brief Pain Inventory; FIQR = Revised Fibromyalgia Impact Questionnaire; MAF = Multidimensional Assessment of Fatigue; MCS = Mental Component Summary; PCS = Physical Component Summary; SF-36 = Short Form-36 Health Survey; VAS = Visual Analogue Scale. bBaseline value from lead-in study prior to first milnacipran exposure.